The Industry Expert Theater brings together industry leaders and attendees interested in the latest drug development research. These hour-long educational (non-accredited) presentations take place in the Oncology Professionals Hall on Saturday, Sunday, and Monday.
Saturday, June 3
Biosimilar Monoclonal Antibodies: What Oncologists Need to Know
9:30 AM–10:30 AM
Richard Markus, VP Biosimilars Global Development, Amgen
TECENTRIQ® in Locally Advanced or Metastatic Urothelial Carcinoma (mUC) and Previously Treated Metastatic Non-small Cell Lung Cancer (NSCLC)
12:15 PM–1:15 PM†^
Genentech USA, Inc.
Fairooz Kabbinavar, MD, FACP Principal Medical Director Product Development Oncology, Genentech, Inc.
Current Updates in ALK NSCLC and Brigatinib
3:00 PM–4:00 PM†‡
David Kerstein, Senior Director, Clinical Development, Takeda Oncology
Sunday, June 4
ZEJULA (Niraparib): A Once-Daily Oral Maintenance Treatment For Recurrent Ovarian Cancer Following Response To Platinum-Based Chemotherapy
9:45 AM–10:45 AM‡
Mary Lynne Hedley, President, TESARO
Insights in Immuno-Oncology: How Antigens and the Tumor Microenvironment Can Shape the Antitumor Immune Response
11:30 AM–12:30 PM
Jackson Egen, PhD, Principal Scientist, Department of Oncology Research, Amgen, Inc.
From Evidence to Practice: Biosimilar Trastuzumab and Rituximab
4:15 PM–5:15 PM†
Ho Ung Kim, Head of Strategy and Operations Division, Celltrion Healthcare
Hyuk Chan Kwon, MD, Ph.D., Head of Medical Affairs Department, Celltrion Healthcare
Byoung Seo Choi, Head of Marketing Department, Celltrion Healthcare
Monday, June 5
Extending Overall Survival in Patients with Relapsed or Refractory Multiple Myeloma: Head-to-Head Study Results
9:30 AM - 10:30 AM†
Sanjay Aggarwal, MD, Executive Medical Global Development, Amgen
Recent accelerated approval of Bavencio, a checkpoint inhibitor
11:30 AM–12:30 PM‡
EMD Serono - Pfizer Alliance
Kevin Chin, Vice President –Clinical Development, EMD Serono
Kanwarjit Singh, MD, Team Leader, Oncology Medical Affairs, Pfizer
†Only individuals with an attendee designation on their badge will be admitted.
‡Presentation intended for a U.S. audience only.
^This presentation is intended for US-based HCPs